



Besponsa® (inotuzumab ozogamicin)

Last Review Date: October 8, 2019

Number: MG.MM.PH.47

Medical Guideline Disclaimer

Property of EmblemHealth. All rights reserved. The treating physician or primary care provider must submit to EmblemHealth the clinical evidence that the patient meets the criteria for the treatment or surgical procedure. Without this documentation and information, EmblemHealth will not be able to properly review the request for prior authorization. The clinical review criteria expressed below reflects how EmblemHealth determines whether certain services or supplies are medically necessary. EmblemHealth established the clinical review criteria based upon a review of currently available clinical information (including clinical outcome studies in the peer-reviewed published medical literature, regulatory status of the technology, evidence-based guidelines of public health and health research agencies, evidence-based guidelines and positions of leading national health professional organizations, views of physicians practicing in relevant clinical areas, and other relevant factors). EmblemHealth expressly reserves the right to revise these conclusions as clinical information changes, and welcomes further relevant information. Each benefit program defines which services are covered. The conclusion that a particular service or supply is medically necessary does not constitute a representation or warranty that this service or supply is covered and/or paid for by EmblemHealth, as some programs exclude coverage for services or supplies that EmblemHealth considers medically necessary. If there is a discrepancy between this guideline and a member's benefits program, the benefits program will govern. In addition, coverage may be mandated by applicable legal requirements of a state, the Federal Government or the Centers for Medicare & Medicaid Services (CMS) for Medicare and Medicaid members. All coding and web site links are accurate at time of publication. EmblemHealth Services Company LLC, ("EmblemHealth") has adopted the herein policy in providing management, administrative and other services to HIP Health Plan of New York, HIP Insurance Company of New York, Group Health Incorporated, GHI HMO Select, ConnectiCare, Inc., ConnectiCare Insurance Company, Inc. ConnectiCare Benefits, Inc., and ConnectiCare of Massachusetts, Inc. related to health benefit plans offered by these entities. All of the aforementioned entities are affiliated companies under common control of EmblemHealth Inc.

Definitions

Besponsa (inotuzumab ozogamicin) is a humanized CD22-directed monoclonal antibody-drug conjugate which is composed of the IgG4 kappa antibody inotuzumab (which is specific for human CD22), a calicheamicin component (a cytotoxic agent that causes double-stranded DNA breaks), and an acid-cleavable linker that covalently binds the calicheamicin to inotuzumab. After the antibody-drug conjugate binds to CD22, the CD22-conjugate complex is internalized, and releases calicheamicin. Calicheamicin binds to the minor groove of DNA to induce double strand cleavage and subsequent cell cycle arrest and apoptosis.

Besponsa (inotuzumab ozogamicin) is indicated for the treatment of adults with relapsed or refractory B-cell precursor acute lymphoblastic leukemia (ALL).

Dosing

Max Units (per dose and over time):

- Cycle 1
 - 27 billable units on Day 1, 18 billable units on Day 8 and Day 15 of a 21 to 28-day cycle
- Subsequent Cycles (maximum of 5 cycles)
 - 27 billable units on Day 1, 18 billable units on Day 8 and Day 15 of a 28-day cycle for up to 2 cycles

- 18 billable units on Day 1, Day 8, and Day 15 of a 28-day cycle for up to 3 cycles

Guideline

Besponsa (inotuzumab ozogamicin) may be considered medically necessary for the following diagnoses when subsequent criteria are met:

B-cell precursor acute lymphoblastic leukemia (ALL):

- Patient is 18 years of age or older; **AND**
- Patient has CD22-positive disease; **AND**
- Besponsa will be used as single agent therapy; **AND**
- Patient has relapsed or refractory disease; **AND**
 - Patient is Philadelphia chromosome (Ph)-negative; **OR**
 - Patient is Philadelphia chromosome (Ph)-positive and failed previous therapy with a tyrosine kinase inhibitor; **AND**
- Besponsa will be used as single agent therapy

Limitations/Exclusions

- Approval will be granted for 6 months, and may not be renewed

Revisions

12/3/2018	Added J9229 and removed C9028 from Applicable Procedure Codes.
-----------	--

Applicable Procedure Codes

J9229	Injection, inotuzumab ozogamicin, 0.1 mg
-------	--

Applicable Diagnosis Codes

C91.00	Acute lymphoblastic leukemia not having achieved remission
C91.01	Acute lymphoblastic leukemia, in remission
C91.02	Acute lymphoblastic leukemia, in relapse

References

1. Besponsa [package insert]. Philadelphia, PA; Pfizer Inc., March 2018. Accessed October 2019.
2. Kantarjian HM, DeAngelo DJ, Stelljes M, et al. Inotuzumab Ozogamicin versus Standard Therapy for Acute Lymphoblastic Leukemia. *N Engl J Med*. 2016 Aug 25;375(8):740-53.
3. 3. Referenced with permission from the NCCN Drugs & Biologics Compendium (NCCN Compendium®) inotuzumab ozogamicin. National Comprehensive Cancer Network, 2017. The NCCN Compendium® is a derivative work of the NCCN Guidelines®. NATIONAL COMPREHENSIVE CANCER NETWORK®, NCCN®, and NCCN GUIDELINES® are trademarks owned by the National Comprehensive Cancer Network, Inc.” To view the most recent and complete version of the Compendium, go online to NCCN.org. Accessed August 2017.